When comparing serum BD-tau level on day 7 with clinical outcome at 1 year in both outcome groups, we found a smaller decrease in BD-tau level in the unfavorable (by day 7: 35.1% [from 191.4 to 124.2 pg/mL]; by day 365: 97.0% [from 124.2 to 3.1 pg/mL]) vs favorable (by day 7: 41.8% [from 75.6 to 44.0 pg/mL]; by day 365: 70.5% [from 44.0 to 13.0 pg/mL]) outcome group (Table). This evidence concerns the gene MAPT and Behcet disease.